Delstrigo® (doravirine/lamivudine/tenofovir DF) Tablets for HIV-1

What Delstrigo Is and How It Works

Delstrigo® is a once-daily complete HIV-1 treatment that combines doravirine, lamivudine, and tenofovir disoproxil fumarate in one tablet. It is used in adults and certain adolescents who are treatment-naive or are replacing a stable regimen without resistance to its components. Many people compare Delstrigo price and look for Delstrigo without insurance options because long-term therapy adds up. You can order through YouDrugstore, a licensed Canadian pharmacy based in Manitoba, where prescriptions are reviewed by licensed pharmacists before dispensing.

Delstrigo® belongs to two classes: doravirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI); lamivudine and tenofovir DF are nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs). Together they block HIV reverse transcriptase and reduce viral replication. The tablet is taken by mouth once daily with or without food. We work with licensed, vetted international partner pharmacies when needed to source authentic brand medications and keep a broad selection at affordable pricing.

YouDrugstore offers brand and select generic medicines at Canadian prices, with friendly customer-service chat during posted office hours. Pharmacists are available to address medication questions related to your prescription.

Dosage and Usage

Follow the regimen prescribed by the clinician. The usual adult dose is one tablet once daily.

• Start: one Delstrigo® tablet by mouth once a day, with or without food.
• Titration: no routine titration; lab monitoring guides ongoing care.
• Missed dose: take the missed dose the same day when remembered. If the next dose is near, skip the missed dose. Do not double up.
• Drug interactions: avoid strong CYP3A inducers (for example rifampin, carbamazepine, phenytoin, St. John’s wort). Do not coadminister with other doravirine, lamivudine, or tenofovir DF products.

• Storage: store at 20–25°C (68–77°F). Keep the bottle tightly closed with the desiccant inside. Protect from moisture.
• Travel: keep tablets in the original labeled bottle in your carry-on. Use a travel pill organizer only for short periods and keep desiccant with the tablets. Avoid leaving medicine in a hot car.

Benefits and Savings

Delstrigo® simplifies therapy with one pill a day. It offers effective viral load reductions in treatment-naive patients without baseline resistance to NNRTIs or to its NRTI components. Doravirine is generally well tolerated and has fewer central nervous system side effects than older NNRTIs.

Ordering through YouDrugstore may offer 60–80% savings versus typical U.S. retail pricing. Many people pay less even when buying without insurance. Multi-month supplies can lower the per-month cost, and reorder reminders can help you stay on schedule.

Side Effects and Safety

Most people tolerate Delstrigo® well. Side effects can still occur. This is not a full list.

• Common: nausea, diarrhea, headache, dizziness, fatigue, abnormal dreams.
• Lab changes: increased creatinine, decreased phosphate, changes in bone mineral density with tenofovir DF.
• Serious: kidney injury or Fanconi syndrome, lactic acidosis, severe hepatomegaly with steatosis, severe skin or hypersensitivity reactions, immune reconstitution inflammatory syndrome.
• Hepatitis B: severe acute exacerbations of hepatitis B can occur after stopping lamivudine or tenofovir DF in coinfected patients; careful monitoring is needed.
• Renal function: the fixed-dose tablet is not recommended if creatinine clearance is below 50 mL/min because individual component dosing is required.
• Drug interactions: strong CYP3A inducers can lower doravirine levels and reduce efficacy; avoid coadministration.

Pregnancy and breastfeeding considerations require individualized medical guidance. Breastfeeding is generally not recommended in HIV to reduce the risk of transmission.

Onset Time

Viral load often begins to decline within one to two weeks of consistent daily dosing. Many patients see marked reductions by four weeks, with continued improvement over the following months. The exact timeline varies with baseline viral load, adherence, and resistance profile. Providers track progress with routine viral load and CD4 testing.

Compare With Alternatives

Several once-daily complete regimens are available, and selection depends on resistance, comorbidities, kidney and bone health, and potential interactions.

Biktarvy: bictegravir/emtricitabine/tenofovir alafenamide. It is an integrase inhibitor–based regimen with a strong barrier to resistance and a kidney- and bone-friendly tenofovir form (TAF). See Biktarvy® to compare ingredients and suitability.

Dovato: dolutegravir/lamivudine. A two-drug regimen appropriate for select treatment-naive adults without HBV coinfection and with certain baseline conditions met. For a two-drug option, review Dovato® details and discuss clinical fit.

Older NNRTI-based options such as efavirenz-containing regimens may have more central nervous system effects. Integrase inhibitor–based regimens are common for many starters. The best choice should reflect resistance testing, medical history, and drug-drug interactions.

Combination Therapy

Delstrigo® is a complete regimen and should not be used with other antiretroviral products. Do not combine with lamivudine, emtricitabine, or tenofovir-containing products, or with other doravirine products. If opportunistic infection prophylaxis, vaccines, or comorbidity treatments are needed, the care team will select agents to avoid interactions and overlapping toxicities.

Patient Suitability and Cost-Saving Tips

Delstrigo® may suit adults and adolescents who are treatment-naive or stable on a compatible regimen, with no known resistance to doravirine, lamivudine, or tenofovir DF. It is generally not recommended for patients with creatinine clearance below 50 mL/min. Those with risk for bone loss or kidney disease need close monitoring on tenofovir DF–containing regimens. Hepatitis B coinfection requires careful planning before any changes to therapy.

You can lower costs by choosing a 90-day supply when appropriate, which often reduces the monthly price. YouDrugstore offers gentle reorder reminders so you can plan ahead. For current promotions, see our Delstrigo coupon options and bulk savings. Some patients also ask about Delstrigo cost without insurance; Canadian pricing may still compare well to U.S. cash prices.

YouDrugstore is a licensed Canadian pharmacy that meets Canadian pharmacy standards and ships to the U.S. Our team supports you with clear ordering, verified dispensing, and attentive service.

Authoritative Sources

Review the manufacturer information on the Merck Delstrigo Prescribing Information. Check the Health Canada Drug Product Database entry for Delstrigo. For U.S. consumer guidance, see the FDA-approved labeling.

You can count on YouDrugstore for careful pharmacy review and discreet packing. Order today for prompt, express, cold-chain shipping to your U.S. address.

This content is for general information. It does not replace the advice of your healthcare provider. Always follow the directions provided with your prescription and the guidance of your care team.